70837-19-3

Usage

Uses

Used in Pharmaceutical Industry:
Methyl-2-aminopent-4-enoate is used as a building block for the preparation of various pharmaceuticals and biologically active compounds. Its presence in the synthesis process allows for the creation of a wide range of drugs with different therapeutic effects, making it an essential component in drug development.
Used in Medicinal Chemistry:
In medicinal chemistry, Methyl-2-aminopent-4-enoate is used as an intermediate in the synthesis of complex organic molecules with potential medicinal properties. Its ability to form various chemical bonds and its compatibility with other compounds make it a valuable asset in the development of new drugs and therapies.
Used in Agrochemical Production:
Methyl-2-aminopent-4-enoate is also used as an intermediate in the production of agrochemicals. Its role in the synthesis of these compounds contributes to the development of effective pesticides, herbicides, and other agricultural products that are crucial for maintaining crop health and productivity.
Used in Flavoring Agent Synthesis:
In the flavor and fragrance industry, Methyl-2-aminopent-4-enoate is used as an intermediate for the synthesis of flavoring agents. Its unique chemical structure allows it to contribute to the creation of distinct tastes and scents, enhancing the sensory experience of various consumer products.
Overall, Methyl-2-aminopent-4-enoate is a versatile and important chemical that has various applications in the pharmaceutical, chemical, agrochemical, and flavoring industries. Its unique structure and reactivity make it a valuable component in the synthesis of a wide range of products, from life-saving drugs to everyday consumer goods.

Upstream product

• 67-56-1 methanol 
• 1069-48-3 rac-allylglycine 
• 150374-52-0 Methyl 2-(benzylideneamino)pent-4-enoate 
• 16338-48-0 L-allylglycine 
• 81177-53-9 (2S,5R)-5-Allyl-2-(3,4-dimethoxy-benzyl)-3,6-dimethoxy-2-methyl-2,5-dihydro-pyrazine 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 119244-19-8 tert-butyl (S)-2-[(diphenylmethylene)amino]pent-4-enoate 
• 106928-50-1 methyl 2-[(tert-butoxycarbonyl)amino]pent-4-enoate 
• 119479-32-2 2-((tert-butyloxycarbonyl)amino)-4-pentenoic acid 
• 143730-35-2 (2R,5S)-5-Allyl-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine 
• 128474-85-1 methyl glyoxylate oxime 
• 24850-33-7 allyltributylstanane 
• 1363553-52-9 methyl 2-(4,5-dimethoxy-2-methylbenzylamino)pent-4-enoate 
• 115289-55-9 methyl DL-2-amino-4-pentenoate hydrochloride 

Downstream Products

• 1069-48-3 rac-allylglycine 
• 106928-50-1 methyl 2-[(tert-butoxycarbonyl)amino]pent-4-enoate 
• 252648-41-2 2-(Toluene-4-sulfonylamino)pent-4-enoic acid methyl ester 
• 846034-31-9 N-(2,4-dimethoxybenzyl)-allylglycine methyl ester 
• 133787-04-9 methyl (RS)-N-phthaloyl-2-amino-4-pentenoate 
• 784155-47-1 benzyl 4-{[1-(methoxycarbonyl)but-3-en-1-yl]amino}piperidine-1-carboxylate 
• 93267-06-2 (S)-2-(Toluene-4-sulfonylamino)pent-4-enoic acid methyl ester 
• 851909-03-0 N-(N-(Boc)-L-homoallylglycyl)-N-(2,4-dimethoxybenzyl)-L-allylglycine methyl ester 
• 851908-96-8 methyl (E,3S,9S)-3-N-(Fmoc)amino-1-(2,4-dimethoxybenzyl)-2-oxo-2,3,4,5,8,9-hexahydro-1H-azonine-9-carboxylate 
• 851909-04-1 N-(N-(Fmoc)-L-homoallylglycyl)-N-(2,4-dimethoxybenzyl)-L-allylglycine methyl ester 
• 336879-49-3 N-(N-Boc-L-allylglycyl)-N-(2,4-dimethoxybenzyl)-L-allylglycine methyl ester 
• 794514-81-1 (S)-methyl 2-(2-nitrophenylsulfonamido)pent-4-enoate 
• 141083-85-4 (S)-methyl 1,2,3,6-tetrahydropyridine-2-carboxylate 
• 116613-81-1 (S)-tert-butyl (1-hydroxypent-4-en-2-yl)carbamate 

Relevant academic research and scientific papers

Enantioenriched α-substituted glutamates/pyroglutamates via enantioselective cyclopropenimine-catalyzed Michael addition of amino ester imines

A procedure for the enantioselective synthesis of α-substituted glutamates and pyroglutamates via a cyclopropenimine-catalyzed Michael addition of amino ester imines is described. Enantioselectivities of up to 94% have been achieved, and a variety of functional groups were found to be compatible. The impact of the catalyst structure and imine substitution is discussed. Compared to other methods, this protocol allows for a broader and more enantioselective access to pyroglutamate derivatives.

Diaminopimelic acid (DAP) analogs bearing isoxazoline moiety as selective inhibitors against meso-diaminopimelate dehydrogenase (m-Ddh) from Porphyromonas gingivalis

Two diastereomeric analogs (1 and 2) of diaminopimelic acid (DAP) bearing an isoxazoline moiety were synthesized and evaluated for their inhibitory activities against meso-diaminopimelate dehydrogenase (m-Ddh) from the periodontal pathogen, Porphyromonas

Optically Pure, Structural, and Fluorescent Analogues of a Dimeric Y4 Receptor Agonist Derived by an Olefin Metathesis Approach

The dimeric peptide 1 (BVD-74D, as a diastereomeric mixture) is a potent and selective neuropeptide Y Y4 receptor agonist. It represents a valuable candidate in developing traceable ligands for pharmacological studies of Y4 receptors

SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS

The present invention relates to compounds of the general formula (I) having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with

Synthesis of skeletally diverse alkaloid-like molecules: Exploitation of metathesis substrates assembled from triplets of building blocks

A range of metathesis substrates was assembled from triplets of unsaturated building blocks. The approach involved the iterative attachment of a propagating and a terminating building block to a fluorous-tagged initiating building block. Metathesis cascade chemistry was used to "reprogram" the molecular scaffolds. Remarkably, in one case, a cyclopropanation reaction competed with the expected metathesis cascade process. Finally, it was demonstrated that the metathesis products could be derivatised to yield the final products. At each stage, purification was facilitated by the presence of a fluorous-tagged protecting group.

New histone deacetylase inhibitors based on 4-fluoro-2-amino acid esters: Synthesis and activity

A series of twelve fluorinated and non-fluorinated potential histone deacetylase inhibitors 25 was synthesized and their inhibitory activity was tested against rat liver histone deacetylase. The new inhibitors involve an enzyme binding element consisting of asparagine, glutamine or different short chain fluorinated or unfluorinated amino acids, a suberoyl spacer and a hydroxamic acid functionality, which is responsible for the inhibitory activity. The 4-fluoro-2-aminobutyric acid esters 1a,b, their 2-methyl derivatives 2a,b and the 2-amino-4-fluoropent-4-enoic acid esters 3a,b were synthesized by alkylation of glycine or alanine ester imides with bromofluoroethane or 2-fluoroallylbromide, respectively. Methyl 2-amino-5-fluorohex-5-enoate (4a) was prepared using 3-fluorobut-3-enyl tosylate or the iodide as alkylating reagents. An alternative pathway starting from Boc protected 3-iodo-L-alanine was more efficient. The latter method was also applied to synthesize the parent unfluorinated compound 4c using allylbromide as the alkylating reagent. The fluorinated compounds, tested as histone deacetylase inhibitors were slightly less active than comparable (S)-valine, (S)-phenylalanine or (S)-allylglycine derivatives that do not contain a fluorine atom. Interestingly, it was shown for the first time that the fluoro vinyl group which was proposed to be an aprotic amide mimic due to its electronic properties may serve as a bioisosteric replacement of a primary amide function. For the fluorinated analogs 25f (IC50 0.88 μM) and 25i (IC50 1.02 μM) a similar or an even enhanced inhibitory activity was observed compared to the unfluorinated parents 25g (IC50 0.67 μM) and 25j (IC50 1.79 μM) or the (S)-asparagine or (S)-glutamine derivatives 25l (IC50 2.10 μM) and 25m (IC50 3.90 μM).

1,2-Dimethoxy-4,5-dimethylene: A new protecting group for acyclic amino acid derivatives prepared by Stevens rearrangement

A new protecting group, 1,2-dimethoxy-4,5-dimethylene, for acyclic amino acid derivatives could be introduced by N,N-dialkylation with 1,2-bis(bromomethyl)-4,5-dimethoxybenzene (1) and removed via amine de-alkylation with acyl chlorides. The method can be used with base-induced [2,3] and [1,2] Stevens rearrangement products.

Remote stereocontrol in reactions between 4- and 5-alkoxyalk-2- enylstannanes and 1-alkoxycarbonylimines and analogues: Stereoselective approaches to novel α-amino acids

Reactions of the allyltin trichloride 45 generated from (4S)-4-benzyloxypent-2-enyl(tributyl)stannane 1 with imines prepared from glyoxylates proceed with useful levels of 1,5-stereocontrol in favour of (4E)-2,6-anti-2-(alkylamino)-6-benzyloxyhept-4-enoat

LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT

This invention provides compounds of formula (I) or its pharmacologically acceptable salt or solvate, wherein A represents aryl or a monocyclic or bicyclic heterocyclic group, R1 represents a halide, nitro, substituted C1-6 alkyl, optionally substituted amino, C1-6 alkyloxycarbonyl, optionally substituted aryl, a heterocyclic group, or heterocyclic carbonyl, R2 represents a hydrogen atom or C1-6 alkyl, R3 represents C1-6 alkyl, all of R4, R5, and R6 represent a hydrogen atom, R7 represents C1-6 alkyl, m is 1 or 2, and n is 1. The compounds are novel lincomycin derivatives having a potent activity against resistant pneumococci. The compounds can be used as an antimicrobial agent and are useful for preventing or treating bacterial infectious diseases.

BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS

The present invention is directed to bridged aryl piperazine derivatives, pharmaceutical compositions containing them and their use in the treatment of depression and related disorders. The compounds of the present invention are serotonin transport inhibi